Test Price
2,800 AED✅ Home Collection Available
VPS53 Gene Pontocerebellar Hypoplasia Type 2E Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل الجين VPS53 المرتبط بنقص تنسج الجسر المخيخي من النوع 2E في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
This definitive Next-Generation Sequencing (NGS) test analyzes the entire coding region of the VPS53 gene to confirm or rule out Pontocerebellar Hypoplasia Type 2E (PCH2E), a severe autosomal recessive neurodevelopmental disorder. Conducted in our DHA-licensed, ISO 9001:2015 certified facility, the assay delivers 99.9% diagnostic sensitivity for relevant SNVs, indels, and copy number variations. يقدم هذا التحليل تشخيصًا جينيًا دقيقًا وموثوقًا لمتلازمة نقص تنسج الجسر المخيخي من النوع 2E، معتمدًا من هيئة الصحة بدبي (DHA) ووفقًا لأحدث إرشادات 2026. Comprehensive pre- and post-test genetic counseling is included, alongside premium home collection services.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited NGS Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy (8 AM - 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed specialists.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Overview
The VPS53 Gene Pontocerebellar Hypoplasia Type 2E NGS test detects pathogenic variants in the VPS53 gene, critical for diagnosing PCH2E, a condition presenting with profound intellectual disability, progressive microcephaly, and early-onset movement disorders. This test is indispensable for definitive diagnosis, carrier screening, and guiding reproductive planning in affected families.
| Feature | Our Test (NGS, UAE) | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Precision | 99.9% sensitivity for VPS53 SNVs/indels/CNVs | ~95% coverage of VPS53 exonic regions |
| Method | Targeted NGS with MLPA confirmation | Broad capture, often misses deep intronic variants |
| TAT | 3-4 Weeks | 6-12 Weeks |
Physician Insight & Safety Protocol
“As a clinician, I understand that pursuing a genetic diagnosis for a child with neurodevelopmental regression can be emotionally overwhelming. This test provides families with a clear molecular answer, empowering informed medical management and future family planning decisions. However, results must always be interpreted in the context of complete clinical evaluation and genetic counseling.” — Dr. Prabhakar Reddy, DHA License No. 61713011.
Medication Warning: Do not discontinue any prescribed medication without consulting your physician. Genetic test results do not replace ongoing symptomatic care.
Exclusion Criteria & ER Red Flags
- Inability to provide valid informed consent (for minors, legal guardian consent required per UAE CDS Law 2026).
- Severe hemophilia or anticoagulant therapy preventing safe blood draw; consult our home collection team.
- Active febrile illness or acute infection does not invalidate the test but may affect biomarker studies if ordered concurrently.
- Urgent: If the patient experiences seizures, respiratory distress, or loss of consciousness, seek emergency medical care immediately. This test is not a replacement for acute intervention.
Patient FAQ & Clinical Guidance
What is the diagnostic accuracy of this VPS53 genetic test for Pontocerebellar Hypoplasia Type 2E?
Using Next-Generation Sequencing with complementary MLPA analysis, this test achieves a 99.9% diagnostic sensitivity for all pathogenic variants in the VPS53 gene, validated against ISO 15189 standards to provide a definitive molecular confirmation for PCH2E.
كم يستغرق الحصول على نتيجة التحليل، وهل يشمل السعر الاستشارة الوراثية؟
يستغرق إصدار النتيجة من 3 إلى 4 أسابيع، ويشمل السعر (2800 درهم) جلستي استشارة وراثية واحدة قبل الفحص وأخرى بعده، مع خدمة السحب المنزلي المعتمدة من هيئة الصحة بدبي.
Can this be used for prenatal diagnosis or carrier screening?
Yes, once familial pathogenic variant is identified, targeted testing can be applied in chorionic villus sampling or amniocentesis for prenatal diagnosis, and carrier screening is available for at-risk relatives, all following UAE PDPL and DHA reproductive health regulations.
UAE Regulatory Compliance:
- Federal Decree-Law No. 41 of 2024 on Genetic Testing and Health Data (Art. 87)
- CDS Law 2026: Minor consent and parental authorization strictly enforced.
- UAE PDPL: All genetic data processed under data protection law; encrypted and stored locally.
- ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) for laboratory quality management.
Home Collection Service: Available daily 8 AM to 11 PM | WhatsApp Support: +971545488731
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians